Abstract: The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone articles of manufacture of pharmaceutical preparations and novel testosterone therapeutic uses thereof.

Abstract: The present invention contemplates novel neurosteroid derivative compounds, such as derivatives of ganaxolone and allopregnanolone, having improved solubility and bioavailability. The novel neurosteroid derivative compounds are characterized by the following formulas: wherein R1 is methyl or hydrogen, R2 is an ester function (R—C(O)O—), R3 is hydrogen, R4 is alpha or beta hydrogen, R5 is R—CO— or any hydrocarbon structure (R—), and wherein R (in R2 or R5) is independently selected from any structure comprising 10 carbon atoms or fewer, which is linear or branched, saturated or unsaturated, may comprise cyclic or aromatic functions within the structure, and wherein R contains no more than 1 OH or NR2, or 2 ether or thioether functions.

Abstract: A nasally administered cannabinoid semi-solid or viscous liquid composition; nasal methods for administering the nasal pharmaceutical compositions; methods for manufacturing the nasal pharmaceutical compositions; and nasal methods of treating diseases treatable by the nasal pharmaceutical compositions formulated with a cannabinoid or mixtures thereof.

Abstract: There is provided a method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) or a solvate thereof, wherein the administration is once-per-day and intranasal, and the total daily dose of the compound (I) is 50 to 100 ?g.

Abstract: There is provided a method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) or a solvate thereof, wherein the administration is once-per-day and intranasal, and the total daily dose of the compound (I) is 50 to 100 ?g.